Qiagen N.V.. (5/15/23). "Press Release: Qiagen Expands Enzyme Offering to Support Individual Life Science Research Labs Worldwide". Berlin.

	Organisation	Qiagen N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA)
	Group	Qiagen (Group)
	Organisation 2	BLIRT S.A. (Biolab Innovative Research Technologies)
	Group	Qiagen (Group)
	Product	industrial enzyme
	Product 2	contract manufacturing (biologicals)
	Index term	BLIRT–Qiagen: investment, 202205 acquisition 96% ownership stake by Qiagen
	Person	Essakali, Salim (Solis BioDyne 202109– Head of Global Sales + Marketing before Qiagen + Boston Scientific)
	Person 2	Gilardi, John (Qiagen 201211 Investor Relations)

> High-quality enzymes now available as individual products, allowing researchers worldwide to customize their assays and workflows

> Dedicated web shop to easily find enzymes for a wide range of applications, including DNA cloning and amplification

> Strict quality control and physical purity assessment; all enzymes produced on QIAGEN’s own ISO and GMP certified manufacturing facilities

QIAGEN today announced that it makes its high-quality enzymes available as individual products, providing researchers and industrial customers worldwide with the flexibility to customize their assays and workflows. This makes QIAGEN a one-stop shop for all research needs – from dedicated enzymes and sample preparation solutions to automation and bioinformatics solutions.

QIAGEN has been a trusted supplier of enzymes for decades, serving Original Equipment Manufacturer (OEM) customers around the world, contributing to the triumph of many tests. The commercial success of QIAGEN’s own kits has been fueled by these enzymes, with more than 3 billion samples processed so far globally using QIAGEN consumable kits.

From experimentation, measurement and visualization to manipulation of biological processes – enzymes are essential to life sciences. Molecular biologists use enzymes to identify, amplify and sequence genes. Enzyme-driven cloning and DNA recombination technologies have led to life-enhancing treatments by contributing insights into the functions of cells and genes in health and disease. But enzyme quality is critical: the success of every process hinges on the finetuning and purity of the enzyme that catalyzes it.

“We are proud to offer our customers a comprehensive range of specialized enzymes to meet their diverse research needs. Our expanded portfolio and dedicated web shop make it easy for researchers to find and purchase the exact enzyme they need, all while benefiting from QIAGEN’s longstanding expertise and our strict quality control measures,” said Salim Essakali, Vice President and Head of OEM & Enzyme Business at QIAGEN.

With the recent acquisition of BLIRT, S.A., a leading manufacturer of enzymes in Europe, QIAGEN has accelerated its production capacity and expanded research facilities, paving the way for more enzyme development, more standardized recombinant enzymes and molecular biology reagents. QIAGEN makes the portfolio available through a dedicated web shop, currently comprising around 60 products, with more to be added in coming months.

QIAGEN provides specialized enzymes for a wide range of applications, including DNA cloning and amplification using PCR, RNA analysis, labeling, sequencing, nicking, and repairing. With QIAGEN’s portfolio, customers have access to specialized Taq DNA polymerase for PCR and a suite of enzymes to manipulate RNA for downstream analysis of gene expression, including reverse transcriptases, RNA ligases, RNA polymerases, and ribonucleases. In addition, QIAGEN offers reagents and reactants that can clean up samples before taking the next step, which speeds up and enhances amplification and transcription.

All QIAGEN enzymes undergo strict quality control and assessment of physical purity, with quality control reports including specific activity, unit characterization assay, measure of protein concentration, and tests for contamination. All enzymes are produced at QIAGEN’s own ISO and GMP certified manufacturing facilities, in Hilden, Germany, Gdansk, Poland and Beverly, USA.

You can access the web shop here.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2022, QIAGEN employed approximately 6,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Press Contact

Daniela Eltrop
Associate Director Public Relations
Germany: +49 2103 29 11676
Mobile: +49 152 01811676
daniela.eltrop@qiagen.com

Lisa Mannagottera
Associate Manager Public Relations
Germany: +49 2103 29 14181
Mobile: +49 152 01811381
lisa.mannagottera@qiagen.com

Dr. Thomas Theuringer
Senior Director Corporate Communications & Head Of External
Germany: +49 2103 29 11826
U.S.: +1 240 686 7425
The Netherlands: +31 773 55 66 66
thomas.theuringer@qiagen.com

IR Contacts

Phoebe Loh
Senior Director Investor Relations
+49 2103 29 11457
phoebe.loh@qiagen.com
Download VCARD

Alexandra Koenig
Investor Relations Coordinator
+49 2103 29 11709
alexandra.koenig@qiagen.com
Download VCARD

John Gilardi
Vice President
Head of Corporate Communications and Investor Relations
Germany +49 2103 29 11711
U.S. +1 240 686 2222
The Netherlands +31 773 55 66 66
john.gilardi@qiagen.com
Download VCARD

Record changed: 2023-06-14